© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
July 30, 2021
The combination achieved a high objective response rate among patients previously treated with immune checkpoint inhibitors.
June 11, 2021
Benefits in progression-free survival and overall response rate were also observed for the pembrolizumab/lenvatinib arm across risk-defined subgroups.
May 10, 2021
Ultra-high single-dose radiotherapy demonstrated comparable efficacy and safety as curative hypofractionated stereotactic body radiotherapy.
April 27, 2021
Role was highlighted in analysis of phase 3 PROSPER trial of enzalutamide in patients with nonmetastatic castration-resistant prostate cancer.